Q2 2022 IVD China: point-of-care infectious-disease testing outperforms during the latest covid surge

The impact of China’s latest covid-19 surge heads the…

Centralised Diagnostics (CEDx) | Covid-19 testing | In-vitro diagnostics | Infectious Diseases Testing Monitor | Molecular Diagnostics (MDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | IVD Gateway | Molecular Diagnostics (MDx) | Point-of-care testing (POCT) | Tissue Diagnostics (TDx)

Outside of covid-19 diagnostics: Nine out of 16 APAC IVD markets have recovered to pre-pandemic levels

Asia-Pacific (APAC) IVD markets have grown and exceeded…

Centralised Diagnostics (CEDx) | In-vitro diagnostics | Molecular Diagnostics (MDx) | Next Generation Sequencing (NGS) | Tissue Diagnostics (TDx) | Asia | Centralised Diagnostics (CEDx) | Covid-19 testing | Infectious Diseases Testing Monitor | IVD Gateway | Molecular Diagnostics (MDx)